Contents

Current Pharmaceutical Design, Volume 17 - Number 23

Editorial [Hot Topic: Designing New Drugs For High Grade Gliomas (Executive Guest Editor: Guido Frosina)]

, 17(23): 2368 - 2369

Guido Frosina


DOI: 10.2174/138161211797249215




Collateral Damage Control in Cancer Therapy: Defining the Stem Identity in Gliomas

, 17(23): 2370 - 2385

David Hsieh


DOI: 10.2174/138161211797249198




Glioma Stem Cell Maintenance: The Role of the Microenvironment

, 17(23): 2386 - 2401

John M. Heddleston, Masahiro Hitomi, Monica Venere, William A. Flavahan, Kenneth Yang, Youngmi Kim, Sana Minhas, Jeremy N. Rich and Anita B. Hjelmeland


DOI: 10.2174/138161211797249260




The Role of Integrins in Glioma Biology and Anti-Glioma Therapies

, 17(23): 2402 - 2410

Ghazaleh Tabatabai, Jorg-Christian Tonn, Roger Stupp and Michael Weller


DOI: 10.2174/138161211797249189




Targeting the AKT Pathway in Glioblastoma

, 17(23): 2411 - 2420

Kelli A. McDowell, Gregory J. Riggins and Gary L. Gallia


DOI: 10.2174/138161211797249224




Bioenergetics Pathways and Therapeutic Resistance in Gliomas: Emerging Role of Mitochondria

, 17(23): 2421 - 2427

Corinne E. Griguer and Claudia R. Oliva


DOI: 10.2174/138161211797249251




Preclinical Development of Novel Anti-Glioma Drugs Targeting the Endoplasmic Reticulum Stress Response

, 17(23): 2428 - 2438

Axel H. Schonthal, Thomas C. Chen, Florence M. Hofman, Stan G. Louie and Nicos A. Petasis


DOI: 10.2174/138161211797249242




New Perspectives in Glioma Immunotherapy

, 17(23): 2439 - 2467

Antonio Daga, Cristina Bottino, Roberta Castriconi, Rosaria Gangemi and Silvano Ferrini


DOI: 10.2174/138161211797249206




Targeting ErbB Receptors in High-Grade Glioma

, 17(23): 2468 - 2487

Sabina Berezowska and Jurgen Schlegel


DOI: 10.2174/138161211797249233




Webmaster Contact: info@benthamscience.org
Copyright © 2018 Bentham Science